Karin Bergen1, Kerstin Brismar2, Sara Tehrani3. 1. Karolinska Institutet, Department of Clinical Sciences Danderyd Hospital, Division of Internal Medicine, Danderyd Hospital, 182 88 Stockholm, Sweden. Electronic address: karin.bergen@ki.se. 2. Karolinska Institutet, Department of Molecular Medicine and Surgery, Karolinska University Hospital Solna, Rolf Lufts Centrum L1:00, 17176 Stockholm, Sweden. 3. Karolinska Institutet, Department of Clinical Sciences Danderyd Hospital, Division of Internal Medicine, Danderyd Hospital, 182 88 Stockholm, Sweden.
Abstract
INTRODUCTION:Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 (IGFBP-1) play an important role in vascular health. Many patients with type 1 diabetes are medicated with HMG-CoA reductase inhibitors, statins, in order to prevent vascular complications. Yet little is known about the effect of statins on the IGF-1/IGFBP-1 axis in these patients. OBJECTIVES: The aim of this study was to evaluate the effect of atorvastatin treatment on IGF-1 and IGFBP-1 with regards to microvascular function. DESIGN:Twenty patients with type 1 diabetes received either placebo or 80mg atorvastatin for two months in a double-blinded cross-over study. IGF-1 and IGFBP-1 levels were assessed before and after each treatment period. Skin microcirculation was studied using Doppler perfusion imaging during iontophoresis of acetylcholine and sodium nitroprusside to assess endothelium-dependent and endothelium-independent microvascular reactivity, respectively. RESULTS: Treatment with high-dose atorvastatin was associated with a significant decrease in IGF-1 levels compared to placebo (p<0.05, ANOVA repeated measures), whereas no effect was seen on IGFBP-1 or the IGF-1/IGFBP-1 ratio. These variables did not correlate with measurements of skin microvascular reactivity. CONCLUSIONS: The study found that treatment with high-dose atorvastatin was associated with reduced IGF-1 levels, which may indicate a potential negative effect on microvascular function and long-term risk of microangiopathy development.
RCT Entities:
INTRODUCTION:Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 (IGFBP-1) play an important role in vascular health. Many patients with type 1 diabetes are medicated with HMG-CoA reductase inhibitors, statins, in order to prevent vascular complications. Yet little is known about the effect of statins on the IGF-1/IGFBP-1 axis in these patients. OBJECTIVES: The aim of this study was to evaluate the effect of atorvastatin treatment on IGF-1 and IGFBP-1 with regards to microvascular function. DESIGN: Twenty patients with type 1 diabetes received either placebo or 80mg atorvastatin for two months in a double-blinded cross-over study. IGF-1 and IGFBP-1 levels were assessed before and after each treatment period. Skin microcirculation was studied using Doppler perfusion imaging during iontophoresis of acetylcholine and sodium nitroprusside to assess endothelium-dependent and endothelium-independent microvascular reactivity, respectively. RESULTS: Treatment with high-dose atorvastatin was associated with a significant decrease in IGF-1 levels compared to placebo (p<0.05, ANOVA repeated measures), whereas no effect was seen on IGFBP-1 or the IGF-1/IGFBP-1 ratio. These variables did not correlate with measurements of skin microvascular reactivity. CONCLUSIONS: The study found that treatment with high-dose atorvastatin was associated with reduced IGF-1 levels, which may indicate a potential negative effect on microvascular function and long-term risk of microangiopathy development.
Authors: A Adamičková; A Gažová; M Adamička; N Chomaničová; S Valašková; Z Červenák; B Šalingová; J Kyselovič Journal: Physiol Res Date: 2021-12-30 Impact factor: 2.139
Authors: Vanessa Y Tan; Caroline J Bull; Kalina M Biernacka; Alexander Teumer; Tom G Richardson; Eleanor Sanderson; Laura J Corbin; Tom Dudding; Qibin Qi; Robert C Kaplan; Jerome I Rotter; Nele Friedrich; Uwe Völker; Julia Mayerle; Claire M Perks; Jeff M P Holly; Nicholas J Timpson Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090